Overview

Electroporation Potentiated Immunotherapy in Cancer

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Collaborators:
Aalborg University
Danish Cancer Society
Odense University Hospital
Treatments:
Pembrolizumab